DSF/Cu sensitizes tumor cells to cisplatin by targeting aldehyde dehydrogenase (ALDH+) (Macdonagh et al., 2017), impedes ATP hydrolysis to prevent drug efflux (Shukla et al., 2004), enhances the sensitivity of tumor cells to temozolomide by inhibiting proteasomes (Lun et al., 2016), and reduces nuclear factor κB (NF-kB) activity to delay IkB degradation, thereby increasing cell sensitivity to gemcitabine (Guo et al., 2010). The gene discussed is NFKB1; the disease is neoplasm.